Isomorphic Labs, the London-based company that uses AI to design medicines, announced a $5bn Series C on 17 November 2026. Greenoaks and Sequoia Capital co-led the round, which the company said was oversubscribed.
Andreessen Horowitz and several other unnamed investors joined as new backers. Alphabet made what the company called a continued significant investment, and existing investors Thrive Capital, MGX, GV, CapitalG, Temasek and the UK Sovereign AI Fund also took part.
The company did not disclose a valuation. Pharmaphorum put its paper value at an estimated $50bn after the round and reported that it has raised more than $7.7bn since it was founded; Isomorphic Labs has not confirmed either figure.
“Our drug design engine is generating molecules with unprecedented precision and speed.”Sir Demis Hassabis, Founder and CEO, Isomorphic Labs
What Isomorphic Labs does
Isomorphic Labs was founded in 2021 and, according to Tech.eu and pharmaphorum, was spun out of Google DeepMind, which is owned by Alphabet. It is led by Sir Demis Hassabis, its founder and chief executive, and Max Jaderberg, its president. Besides its London headquarters it has offices in Cambridge, Massachusetts, and Lausanne, Switzerland.
Its main technology is a drug design engine called IsoDDE. Tech.eu reported that the platform builds on DeepMind software including AlphaFold, the protein structure prediction system, and that the company's research targets cancer and immune disorders. Isomorphic Labs runs its own drug programmes as well as programmes with partners; pharmaphorum named Johnson & Johnson, Novartis and Eli Lilly as research partners.
No drug candidate has yet entered clinical trials, pharmaphorum reported. The company said its work in oncology and immunology, both in-house and with partners, had produced positive preclinical results that prepare the ground for clinical entry.
Who invested
Greenoaks and Sequoia Capital, both California-based venture firms according to Tech.eu, co-led the round. Neil Mehta, founder and managing partner of Greenoaks, described the discovery and development of new medicines as an optimisation problem of near-limitless size. Konstantine Buhler, a partner at Sequoia Capital, said the company was building basic technology for the future of medicine.
Thrive Capital, which led both of the company's previous external rounds, returned, as did the sovereign and Alphabet-linked investors that joined in May.
What the money is for
Isomorphic Labs listed several uses for the money. It plans to develop IsoDDE further and apply it to new areas of biology, build a network of partners to study the mechanisms of disease, and set up AI-led bioengineering infrastructure around the world.
It will also build translational and clinical development capacity designed around AI, so that it can move its first drug candidates into clinical trials. Hassabis said the round would let the company build foundational biology models, deepen its understanding of disease and push its first therapeutic programmes towards trials.
The funding so far
The Series C came about six months after a $2.1bn Series B in May 2026, which Thrive Capital led and which brought in MGX, Temasek, CapitalG and the UK Sovereign AI Fund. Before that, the company raised $600m in March 2025 in its first external round, also led by Thrive Capital, with Alphabet and GV taking part, Tech.eu reported at the time.
The three disclosed external rounds add up to $7.7bn. The company itself has not published a total.
Company website: isomorphiclabs.com
